Apricus Biosciences has signed a licensing agreement with Laboratoires Majorelle (Majorelle) to market its topical on-demand product ‘Vitaros’ for the treatment of erectile dysfunction (ED), in France, Monaco and certain African countries.
Under the deal, Majorelle will pay an upfront and regulatory milestone amount of $4m to Apricus, which is also eligible to receive $21m in milestone payments on future sales, plus double-digit tiered royalties based on Majorelle’s net sales of Vitaros in French-speaking countries in Africa.
In exchange to the payments, Majorelle will have the exclusive right to commercialise the product in France, Monaco and certain African countries.
In addition, Majorelle has agreed to minimum marketing commitments for the product, including the expansion of its existing sales force in France.
Apricus chief executive officer Richard Pascoe said Majorelle is well-equipped to bring the benefits of Vitaros to patients and health care providers in these important territories.
"With their strong and growing commercial organisation, led by a highly experienced management team, and their impressive financial commitment to marketing Vitaros, we look forward to Majorelle’s successful launch of the only topical on-demand ED treatment in France and other French speaking countries," Pascoe added.
Vitaros has excisting partnerships with Takeda in the UK, Sandoz in Germany, Bracco in Italy, Abbott in Canada and Majorelle in France, Monaco and certain African countries.
The company has also received and reviewed multiple bids for commercialisation rights for Vitaros in the remaining un-partnered territories in Europe and expects to announce more licensing transactions by the end of this year.
Vitaros is a topically-applied cream formulation of alprostadil, a vasodilator, combined with Apricus’ proprietary permeation enhancer DDAIP.HCl. It has been approved for the treatment of ED by the European Health Authorities and by Health Canada.
It is the first topical erectile dysfunction treatment that clinically works with an excellent side effect profile and is also under investigation for wounds, female sexual arousal disorder (FSAD) and Raynaud’s syndrome secondary to scleroderma.
Vitaros presents a major market opportunity for Apricus Bio and its commercial partners.